Atrix Laboratories, Inc.
Drug delivery company reports loss of $0.15 per share
Published in Lab Business Week, June 13th, 2004
For the quarter ended March 31, 2004, the net income applicable to common stock was $2.4 million, or $0.11 income per fully diluted share, compared to a net loss applicable to common stock of $3.0 million, or $0.15 loss per fully diluted share, for the first quarter of 2003.
Total revenue increased 61% to $15.2 million in the first quarter 2004 compared to $9.5 million for the quarter ended March 31, 2003. The revenue increase was due primarily to $7.0 million in sales and royalty revenue earned from the continued growth of the Eligard...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
Source: Lab Business Week (2004-06-13)
More Articles from Lab Business Week
- Aerogen, Inc.
Respiratory disease drug firm's stockholders approve closing of $32.7M financing - Amarin Corporation plc
Neuroscience company reports on restructuring, financials - AmeriPath, Inc.
Cancer diagnostics company reports financials after merger - American Oriental Bioengineering
Double-digit revenue, income growth expected by Chinese biotech firm - Amicus Therapeutics, Inc.
Drug development company raises $31M in series B financing - AmpliMed Corp.
Chemotherapy developer completes extended series A financing - More from this issue of Lab Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
